Meme Kanseri Tedavisinde Kullanılan Kemoterapotiklerin Toksisite Yönetimi
Özet
Meme kanseri, dünya genelinde kadınlarda en sık görülen malignite olup, yüksek morbidite ve mortalite oranları ile önemli bir halk sağlığı problemidir. Tedavi yaklaşımı hastalığın evresine ve moleküler alt tipine göre değişir, sistemik tedavi çoğu hasta için temel bileşenlerden biridir. Kemoterapi, özellikle erken evre, lokal ileri ve metastatik hastalıkta genellikle başvurulan sistemik tedavi yöntemlerinden biridir. Ancak, kemoterapi ilaçları tek ajan ya da kombinasyon halinde kullanılabilir, çeşitli oranlarda görülebilen önemli toksik etkilerle ilişkilidir. Bu toksisiteler, tedaviye uyumu azaltabilir, yaşam kalitesini olumsuz etkileyebilir ve kimi durumlarda tedavi rejimlerinin aksamasına ve duraksamasına yol açabilir. Toksisite yönetimi tedavi devamlılığı için önemlidir, bu bölümde meme kanserinde kullanılan kemoterapi ajanlarının sık görülen yan etkilerini ele alacağız.
Referanslar
Twelves C, Jove M, Gombos A, Awada A. Cytotoxic chemotherapy: still the mainstay of clinical practice for all subtypes metastatic breast cancer. Crit Rev Oncol Hematol. 2016 Apr;100:74–87. doi: 10.1016/j.critrevonc.2016.01.021.
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E; ESMO Guidelines Committee. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Aug 1;30(8):1194–1220. doi: 10.1093/annonc/mdz173.
González-Neira A. Pharmacogenetics of chemotherapy efficacy in breast cancer. Pharmacogenomics. 2012 Apr;13(6):677–90. doi: 10.2217/pgs.12.44.
Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012 Apr;82(1):51–77. doi: 10.1016/j.critrevonc.2011.04.012.
Rivera DR, Ganz PA, Weyrich MS, Bandos H, Melnikow J. Chemotherapy-associated peripheral neuropathy in patients with early-stage breast cancer: a systematic review. J Natl Cancer Inst. 2018 Feb 1;110(2):djx140. doi: 10.1093/jnci/djx140.
Jordan B, Margulies A, Cardoso F, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol. 2020;31(10):1306–1319. doi: 10.1016/j.annonc.2020.07.003.
Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol. 2010 Dec;6(12):657–66. doi: 10.1038/nrneurol.2010.160.
Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012 Sep;14 Suppl 4:iv45–54. doi: 10.1093/neuonc/nos203.
Tai HY, Lin LY, Huang TW, Gautama MSN. Efficacy of cryotherapy in the prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Support Care Cancer. 2024 Jul 2;32(7):482. doi: 10.1007/s00520-024-08680-3.
Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, Ripamonti CI; ESMO Guidelines Committee. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv166–iv191. doi: 10.1093/annonc/mdy152.
Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013 Apr 3;309(13):1359–67. doi: 10.1001/jama.2013.2813.
Oikawa M, Ishida T, Takeishi Y. Cancer therapeutics-related cardiovascular dysfunction: basic mechanisms and clinical manifestation. J Cardiol. 2023 Mar;81(3):253–9. doi: 10.1016/j.jjcc.2022.04.006.
Piepoli MF, Adamo M, Barison A, et al. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. Eur J Heart Fail. 2022 Jan;24(1):143–168. doi: 10.1002/ejhf.2351.
Khouri MG, Douglas PS, Mackey JR, et al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation. 2012 Dec 4;126(23):2749–63. doi: 10.1161/CIRCULATIONAHA.112.100560.
Tan TC, Neilan TG, Francis S, et al. Anthracycline-induced cardiomyopathy in adults. Compr Physiol. 2015;5(4):1517–41. doi: 10.1002/cphy.c140059.
Li DL, Wang ZV, Ding G, et al. Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification. Circulation. 2016 Apr 26;133(17):1668–87. doi:10.1161/CIRCULATIONAHA.115.017443.
Chow EJ, Chen Y, Kremer LC, et al. Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol. 2015 Feb 10;33(5):394–402. doi:10.1200/JCO.2014.56.1373.
Zheng H. It is time to abandon the use of body surface area derived from a 100-year-old formula. Am J Med. 2022 Sep;135(9):e308–e310. doi:10.1016/j.amjmed.2022.03.035.
Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013 Oct 10;31(29):3673–80. doi:10.1200/JCO.2013.49.3205.
Daunorubicin hydrochloride injection, solution [Internet]. DailyMed. Bethesda (MD): US National Library of Medicine; 2021 Feb 9 [cited 2022 Oct 24]. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9705fa12-499e-41a3-8fb4-f6df0858b851
Doxorubicin hydrochloride [Internet]. US Food and Drug Administration (FDA) approved product information. New York: Pfizer; 2013 Oct [cited 2022 Jul 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050467s073lbl.pdf
Epirubicin [Internet]. US Food and Drug Administration (FDA) approved product information. New York: Pfizer; 2019 Jul [cited 2022 Jul 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050778s024s025lbl.pdf
Idarubicin hydrochloride – drug summary [Internet]. Prescribers' Digital Reference. [cited 2022 Jul 20]. Available from: https://www.pdr.net/drug-summary/Idamycin-PFS-idarubicin-hydrochloride-1018
Idarubicin – provider monograph [Internet]. Cancer Care Ontario. [cited 2022 Jul 20]. Available from: https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/43861
Mitoxantrone for injection [Internet]. US Food and Drug Administration (FDA) approved product information. Rockland (MA): EMD Serono; 2010 May [cited 2022 Jul 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019297s033s034lbl.pdf
Guglin M, Cutro R, Mishkin JD. Trastuzumab-induced cardiomyopathy. J Card Fail. 2008 Jun;14(5):437–44. doi:10.1016/j.cardfail.2008.02.002.
Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol. 2010 Jul 20;28(21):3416–21. doi:10.1200/JCO.2009.23.6950.
Guenancia C, Lefebvre A, Cardinale D, et al. Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis. J Clin Oncol. 2016 Sep 10;34(26):3157–65. doi:10.1200/JCO.2016.67.4846.
Procter M, Suter TM, de Azambuja E, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 2010 Jul 20;28(21):3422–8. doi:10.1200/JCO.2009.26.0463.
Halyard MY, Pisansky TM, Dueck AC, et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol. 2009 Jun 1;27(16):2638–44. doi:10.1200/JCO.2008.17.9549.
Kim H, Hong B, Kim S, et al. Chemotherapy-related cardiotoxicity and its symptoms in patients with breast cancer: a scoping review. Syst Rev. 2024 Jun 27;13(1):167. doi:10.1186/s13643-024-02588-z.
Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996 Jul 1;125(1):47–58. doi:10.7326/0003-4819-125-1-199607010-00008.
Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000 Apr 13;342(15):1077–84. doi:10.1056/NEJM200004133421502.
Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015 Jan;28(1):1–39.e14. doi:10.1016/j.echo.2014.10.003.
Armstrong GT, Plana JC, Zhang N, et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol. 2012 Aug 10;30(23):2876–84. doi:10.1200/JCO.2011.40.3584.
Danesi R, Fogli S, Gennari A, et al. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet. 2002;41(6):431–44. doi:10.2165/00003088-200241060-00004.
Gaudin PB, Hruban RH, Beschorner WE, et al. Myocarditis associated with doxorubicin cardiotoxicity. Am J Clin Pathol. 1993 Aug;100(2):158–63. doi:10.1093/ajcp/100.2.158.
Abdel-Qadir H, Ong G, Fazelzad R, et al. Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis. Ann Oncol. 2017 Mar 1;28(3):628–33. doi:10.1093/annonc/mdw671.
Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016 Jun 1;37(21):1671–80. doi:10.1093/eurheartj/ehw022.
Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006 Sep 1;24(25):4107–15. doi:10.1200/JCO.2005.04.9551.
Kurtin S. Myeloid toxicity of cancer treatment. J Adv Pract Oncol. 2012 Jul;3(4):209–24.
Bidadi B, Liu D, Kalari KR, et al. Pathway-based analysis of genome-wide association data identified SNPs in HMMR as biomarker for chemotherapy-induced neutropenia in breast cancer patients. Front Pharmacol. 2018 Mar 13;9:158. doi:10.3389/fphar.2018.00158.
Quartino AL, Karlsson MO, Lindman H, et al. Characterization of endogenous G-CSF and the inverse correlation to chemotherapy-induced neutropenia in patients with breast cancer using population modeling. Pharm Res. 2014 Dec;31(12):3390–403. doi:10.1007/s11095-014-1429-9.
Li X, Zheng H, Yu MC, et al. Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis. Support Care Cancer. 2020 Nov;28(11):5085–97. doi:10.1007/s00520-020-05603-w.
Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol. 2014 Jun;90(3):190–9. doi:10.1016/j.critrevonc.2013.12.006.
Cullen MH, Billingham LJ, Gaunt CH, et al. Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol. 2007 Oct 20;25(30):4821–8. doi:10.1200/JCO.2006.08.7395.
Hosmer W, Malin J, Wong M. Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer. 2011 Mar;19(3):333–41. doi:10.1007/s00520-010-0821-1.
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/ (Accessed on September 05, 2024).
NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors, Version 1.2012. Available at: http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf (Accessed on May 21, 2012).
Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015 Oct 1;33(28):3199–212. doi:10.1200/JCO.2015.62.3488.
Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011 Feb 15;52(4):e56–93. doi:10.1093/cid/cir073.
Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2016 Sep;27(suppl 5):v111–v118. doi:10.1093/annonc/mdw325.
Forsgård RA, Korpela R, Holma R, et al. Intestinal permeability to iohexol as an in vivo marker of chemotherapy-induced gastrointestinal toxicity in Sprague-Dawley rats. Cancer Chemother Pharmacol. 2016 Oct;78(4):863–74. doi:10.1007/s00280-016-3150-3.
Forsgård RA, Marrachelli VG, Korpela K, et al. Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague-Dawley rats. Cancer Chemother Pharmacol. 2017 Aug;80(2):317–32. doi:10.1007/s00280-017-3364-z.
McQuade RM, Stojanovska V, Abalo R, et al. Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments. Front Pharmacol. 2016 Nov 3;7:414. doi:10.3389/fphar.2016.00414.
Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020 Aug 20;38(24):2782–97. doi:10.1200/JCO.20.01296.
Herrstedt J, et al. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open. 2024;9(2):102195. doi:10.1016/j.esmoop.2024.102195.
